Literature DB >> 18819102

Interleukin-4 activates androgen receptor through CBP/p300.

Soo Ok Lee1, Jae Yeon Chun, Nagalakshmi Nadiminty, Wei Lou, Siting Feng, Allen C Gao.   

Abstract

BACKGROUND: Aberrant activation of androgen receptor (AR) plays an important role in the progression of castration resistant prostate cancer. Interleukin-4 (IL-4) enhances AR activation in the absence of androgen and stimulates castration resistant growth of androgen-sensitive prostate cancer cells. However, the mechanism of IL-4 mediated AR activation has not yet been revealed.
METHODS: The effect of IL-4 on CBP/p300 expression was examined by Western blot analysis. The effect of IL-4 on the interactions of AR and CBP/p300 was examined by co-immunoprecipitation and ChIP assays. CBP/p300 siRNA was used to knockdown CBP/p300 expression to examine the role of CBP/p300 expression on IL-4 mediated AR activation.
RESULTS: We found that IL-4 increases CBP/p300 protein expression and enhances interaction of AR with CBP/p300 proteins through an increase in the recruitment of CBP/p300 protein to the androgen responsive elements in the promoters of androgen responsive genes. Down regulation of CBP/p300 expression using CBP/p300 specific siRNA abolished IL-4 mediated AR activation, suggesting that CBP/p300 is responsible for AR activation induced by IL-4. Furthermore, AR activation can be enhanced by AR acetylation induced by IL-4 in prostate cancer cells. The IL-4 mediated AR acetylation can be blocked by knocking down CBP/p300 expression using CBP/p300 specific siRNA.
CONCLUSION: These results suggest that IL-4 activates AR through enhanced expression of CBP/p300 and its histone acetyltransferase activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18819102      PMCID: PMC3035998          DOI: 10.1002/pros.20865

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  39 in total

1.  The acetyltransferase activity of CBP stimulates transcription.

Authors:  M A Martinez-Balbás; A J Bannister; K Martin; P Haus-Seuffert; M Meisterernst; T Kouzarides
Journal:  EMBO J       Date:  1998-05-15       Impact factor: 11.598

2.  The CBP co-activator is a histone acetyltransferase.

Authors:  A J Bannister; T Kouzarides
Journal:  Nature       Date:  1996 Dec 19-26       Impact factor: 49.962

3.  A family of transcriptional adaptor proteins targeted by the E1A oncoprotein.

Authors:  Z Arany; D Newsome; E Oldread; D M Livingston; R Eckner
Journal:  Nature       Date:  1995-03-02       Impact factor: 49.962

4.  Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells.

Authors:  B A Witthuhn; O Silvennoinen; O Miura; K S Lai; C Cwik; E T Liu; J N Ihle
Journal:  Nature       Date:  1994-07-14       Impact factor: 49.962

5.  Structural basis for IL-4 receptor phosphopeptide recognition by the IRS-1 PTB domain.

Authors:  M M Zhou; B Huang; E T Olejniczak; R P Meadows; S B Shuker; M Miyazaki; T Trüb; S E Shoelson; S W Fesik
Journal:  Nat Struct Biol       Date:  1996-04

6.  Both interleukin 4 and interleukin 13 induce tyrosine phosphorylation of the 140-kDa subunit of the interleukin 4 receptor.

Authors:  C Smerz-Bertling; A Duschl
Journal:  J Biol Chem       Date:  1995-01-13       Impact factor: 5.157

7.  IL-13 induces phosphorylation and activation of JAK2 Janus kinase in human colon carcinoma cell lines: similarities between IL-4 and IL-13 signaling.

Authors:  T Murata; P D Noguchi; R K Puri
Journal:  J Immunol       Date:  1996-04-15       Impact factor: 5.422

8.  Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene.

Authors:  K Shimoda; J van Deursen; M Y Sangster; S R Sarawar; R T Carson; R A Tripp; C Chu; F W Quelle; T Nosaka; D A Vignali; P C Doherty; G Grosveld; W E Paul; J N Ihle
Journal:  Nature       Date:  1996-04-18       Impact factor: 49.962

9.  Role of IRS-2 in insulin and cytokine signalling.

Authors:  X J Sun; L M Wang; Y Zhang; L Yenush; M G Myers; E Glasheen; W S Lane; J H Pierce; M F White
Journal:  Nature       Date:  1995-09-14       Impact factor: 49.962

10.  Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.

Authors:  Z Culig; A Hobisch; M V Cronauer; C Radmayr; J Trapman; A Hittmair; G Bartsch; H Klocker
Journal:  Cancer Res       Date:  1994-10-15       Impact factor: 12.701

View more
  15 in total

Review 1.  Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives.

Authors:  Nagalakshmi Nadiminty; Allen C Gao
Journal:  World J Urol       Date:  2011-10-19       Impact factor: 4.226

2.  The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor.

Authors:  Sathish Kasina; Jill A Macoska
Journal:  Mol Cell Endocrinol       Date:  2012-01-08       Impact factor: 4.102

3.  NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.

Authors:  Chuigong Yu; Guojun Wu; Ruixiao Li; Lei Gao; Fan Yang; Yi Zhao; Jian Zhang; Rui Zhang; Jing Zhang; Libo Yao; Jianlin Yuan; Xia Li
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 4.  Minireview: Tipping the balance: ligand-independent activation of steroid receptors.

Authors:  Marcela A Bennesch; Didier Picard
Journal:  Mol Endocrinol       Date:  2015-01-27

Review 5.  Breast and prostate cancer: more similar than different.

Authors:  Gail P Risbridger; Ian D Davis; Stephen N Birrell; Wayne D Tilley
Journal:  Nat Rev Cancer       Date:  2010-02-11       Impact factor: 60.716

Review 6.  Cell mates: paracrine and stromal targets for prostate cancer therapy.

Authors:  Pavel Sluka; Ian D Davis
Journal:  Nat Rev Urol       Date:  2013-07-16       Impact factor: 14.432

7.  Associations between polymorphisms in the IL-4 and IL-4 receptor genes and urinary carcinomas: a meta-analysis.

Authors:  Yun Luo; Zhiqiang Ye; Ke Li; Ruihan Chen; Shigeng Li; Jun Pang
Journal:  Int J Clin Exp Med       Date:  2015-01-15

Review 8.  Post-Translational Modifications That Drive Prostate Cancer Progression.

Authors:  Ivana Samaržija
Journal:  Biomolecules       Date:  2021-02-09

Review 9.  KATs in cancer: functions and therapies.

Authors:  A Farria; W Li; S Y R Dent
Journal:  Oncogene       Date:  2015-02-09       Impact factor: 9.867

10.  Integrated network model provides new insights into castration-resistant prostate cancer.

Authors:  Yanling Hu; Yinmin Gu; Huimin Wang; Yuanjie Huang; Yi Ming Zou
Journal:  Sci Rep       Date:  2015-11-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.